Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT04709575 · ClinicalTrials.gov registry record · Phase 3

Study to Assess the Efficacy of Anti-Bet v 1 Monoclonal Antibodies in Adults to Reduce Symptoms of Seasonal Allergic Rhinitis

A Phase 3 study of Allergic Rhinitis and Conjunctivitis, sponsored by Regeneron Pharmaceuticals.

Completed
Registry status
Phase 3
Development phase
353
Enrollment target
20
Study locations

NCT04709575 is a Phase 3 study of Allergic Rhinitis and Conjunctivitis that has completed, run by Regeneron Pharmaceuticals. The registered enrollment target is 353 participants, above the 90-participant average among 23 other Allergic Rhinitis trials with a reported enrollment target (292% higher). The trial reports 20 study locations across 15 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT04709575, a Phase 3 study of Allergic Rhinitis and Conjunctivitis, has completed, sponsored by Regeneron Pharmaceuticals.

COMPLETED
Registry status
Phase 3
Development phase
353 participants
Enrollment target
20
Study locations

Study Summary

The primary objective is to assess the reduction of allergic symptoms as measured by combined symptom and medication score (CSMS) during birch pollen season after a single dose of REGN5713-5714-5715 versus placebo.

Conditions Studied

Allergic Rhinitis Conjunctivitis

Interventions

  • DRUG Placebo
  • DRUG REGN5713
  • DRUG REGN5715
  • DRUG REGN5714

Study Locations (20)

Ontario

  • Regeneron Study Site - Kingston
  • Regeneron Study Site - London
  • Regeneron Study Site - Ottawa
  • Regeneron Study Site - Toronto

Missouri

  • Regeneron Study Site - Columbia
  • Regeneron Study Site - St Louis

Ohio

  • Regeneron Study Site - Cincinnati
  • Regeneron Study Site - Toledo

Maine

  • Regeneron Study Site - Bangor

Maryland

  • Regeneron Study Site - Baltimore

Minnesota

  • Regeneron Study Site - Plymouth

Montana

  • Regeneron Study Site - Missoula

New Jersey

  • Regeneron Study Site - Verona

Trial Details

FieldValue
Enrollment Target 353 participants
Start Date 2021-01-14
Est. Completion 2021-08-24
Phase Phase 3

Sponsor

Regeneron Pharmaceuticals

280 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT04709575

The ClinicalTrials.gov registry entry for NCT04709575 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 353 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 90-participant average among 23 other Allergic Rhinitis trials with a reported enrollment target (292% higher). The listed sponsor is Regeneron Pharmaceuticals, which has 280 total studies on file at ClinicalTrials.gov.

The record links to 2 conditions, with Allergic Rhinitis appearing as the primary indexed condition, and to 4 interventions - of which Placebo is the first listed.

NCT04709575 reports 20 study locations spanning 15 distinct geographic areas - top geographies include Ontario, Missouri, Ohio.

Frequently Asked Questions

What is clinical trial NCT04709575 about?

NCT04709575 is a clinical study titled "Study to Assess the Efficacy of Anti-Bet v 1 Monoclonal Antibodies in Adults to Reduce Symptoms of Seasonal Allergic Rhinitis". The primary objective is to assess the reduction of allergic symptoms as measured by combined symptom and medication score (CSMS) during birch pollen season after a single dose of REGN5713-5714-5715 versus placebo.

What is the current status of trial NCT04709575?

This trial is currently completed. It is a Phase 3 study. The enrollment target is 353 participants. The study started on 2021-01-14. Estimated completion is 2021-08-24.

What conditions does trial NCT04709575 study?

This clinical trial studies the following conditions: Allergic Rhinitis, Conjunctivitis.

What interventions are being tested in trial NCT04709575?

The interventions under investigation include: Placebo (DRUG), REGN5713 (DRUG), REGN5715 (DRUG), REGN5714 (DRUG).

Who is sponsoring clinical trial NCT04709575?

This trial is sponsored by Regeneron Pharmaceuticals, which has 280 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT04709575 being conducted?

This trial has 20 study locations across Maine, Maryland, Minnesota, Missouri, Montana. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Allergic Rhinitis

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Allergic Rhinitis

All registered trials for this condition

Conjunctivitis

All registered trials for this condition

Maine

All trials with a study site in Maine

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.